

Benjamin Djulbegovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7502117/publications.pdf>

Version: 2024-02-01

397
papers

35,096
citations

14614

66
h-index

3714

179
g-index

426
all docs

426
docs citations

426
times ranked

37988
citing authors

#	ARTICLE	IF	CITATIONS
1	Colony-stimulating factors for chemotherapy-induced febrile neutropenia. The Cochrane Library, 2022, 2022, CD003039.	1.5	85
2	A few panel members dominated guideline development meeting discussions: Social network analysis. Journal of Clinical Epidemiology, 2022, 141, 1-10.	2.4	8
3	High quality (certainty) evidence changes less often than low-quality evidence, but the magnitude of effect size does not systematically differ between studies with low versus high-quality evidence. Journal of Evaluation in Clinical Practice, 2022, 28, 353-362.	0.9	5
4	Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias. Journal of Clinical Epidemiology, 2022, 148, 193-195.	2.4	5
5	Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events. Lancet Haematology, the, 2022, 9, e12-e13.	2.2	4
6	Identification of threshold for large (dramatic) effects that would obviate randomized trials is not possible. Journal of Clinical Epidemiology, 2022, 145, 101-111.	2.4	6
7	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncology Practice, 2021, 17, e257-e265.	1.4	8
8	GRADE Guidelines: 29. Rating the certainty in time-to-event outcomes—Study limitations due to censoring of participants with missing data in intervention studies. Journal of Clinical Epidemiology, 2021, 129, 126-137.	2.4	4
9	Evidence, values, and masks for control of COVID-19. Journal of Clinical Epidemiology, 2021, 131, 152-157.	2.4	4
10	Research synthesis of information theory measures of uncertainty: Meta-analysis of entropy and mutual information of diagnostic tests. Journal of Evaluation in Clinical Practice, 2021, 27, 246-255.	0.9	1
11	The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist, 2021, 26, e1418-e1426.	1.9	1
12	Ethics of uncertainty. Patient Education and Counseling, 2021, 104, 2628-2634.	1.0	7
13	Certainty of evidence and intervention's benefits and harms are key determinants of guidelines™ recommendations. Journal of Clinical Epidemiology, 2021, 136, 1-9.	2.4	14
14	GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making. Journal of Clinical Epidemiology, 2021, 129, 138-150.	2.4	81
15	Some thoughts on conducting and implementing clinical practice guidelines in a pandemic. Chinese Medical Journal, 2021, 134, 910-912.	0.9	3
16	Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. Ca-A Cancer Journal for Clinicians, 2021, 71, 78-92.	157.7	230
17	Can we trust strong recommendations based on low quality evidence?. BMJ, The, 2021, 375, n2833.	3.0	12
18	Discordant and inappropriate discordant recommendations in consensus and evidence based guidelines: empirical analysis. BMJ, The, 2021, 375, e066045.	3.0	21

#	ARTICLE	IF	CITATIONS
19	On Occasion of the 12th "Days of AMNuBiH 2021" and "SWEP 2021" Conferences, Sarajevo, Bosnia and Herzegovina. <i>Acta Informatica Medica</i> , 2021, 29, 295.	0.5	1
20	Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 398-406.	1.7	32
21	Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1293-1308.	0.5	3
22	Evaluation of the U.S. governors' decision when to issue stay-at-home orders. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 1347-1351.	0.9	10
23	Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. <i>JAMA Oncology</i> , 2020, 6, 1759.	3.4	64
24	When are randomized trials unnecessary? A signal detection theory approach to approving new treatments based on non-randomized studies. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 27, 735-742.	0.9	2
25	A user guide to the American Society of Hematology clinical practice guidelines. <i>Blood Advances</i> , 2020, 4, 2095-2110.	2.5	14
26	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting: Role of Academic and Hybrid Modeling. <i>Journal of Clinical Medicine</i> , 2020, 9, 1884.	1.0	5
27	Evidence-based medicine in times of crisis. <i>Journal of Clinical Epidemiology</i> , 2020, 126, 164-166.	2.4	25
28	Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review. <i>Journal of Clinical Oncology</i> , 2020, 38, 2558-2569.	0.8	110
29	Evidence vs Consensus in Clinical Practice Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 725.	3.8	67
30	The importance of randomised vs non-randomised trials. <i>Lancet</i> , The, 2019, 394, 634-635.	6.3	7
31	US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials. <i>JAMA Network Open</i> , 2019, 2, e1911111.	2.8	19
32	A forgotten β^3 error. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 751-753.	0.9	0
33	Failure to place evidence at the centre of quality improvement remains a major barrier for advances in quality improvement. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 369-372.	0.9	11
34	Structured decision-making drives guidelines panels' recommendations "for" but not "against" health interventions. <i>Journal of Clinical Epidemiology</i> , 2019, 110, 23-33.	2.4	12
35	Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 1336-1351.	0.8	73
36	Hematological Malignancies and Arterial Thromboembolism. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 611-624.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Tolerating uncertainty about conceptual models of uncertainty in health care. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 183-185.	0.9	13
38	Statins for Primary Prevention of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2019, 171, 73.	2.0	2
39	Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium. <i>Annals of Internal Medicine</i> , 2019, 171, 756.	2.0	227
40	Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. <i>Blood Advances</i> , 2019, 3, 1197-1210.	2.5	76
41	The threshold model revisited. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 186-195.	0.9	33
42	A unifying framework for improving health care. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 358-362.	0.9	21
43	Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2019, 108, 1-9.	2.4	6
44	Precision medicine for individual patients should use population group averages and larger, not smaller, groups. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13031.	1.7	13
45	Diagnostic Predictive Model for Diagnosis of Heart Failure after Hematopoietic Cell Transplantation (HCT): Comparison of Traditional Statistical with Machine Learning Modeling. <i>Blood</i> , 2019, 134, 5799-5799.	0.6	1
46	Transforming clinical practice guidelines and clinical pathways into fast and frugal decision trees to improve clinical care strategies. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 1247-1254.	0.9	36
47	Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval. <i>Journal of Clinical Epidemiology</i> , 2018, 98, 24-32.	2.4	23
48	Expected utility versus expected regret theory versions of decision curve analysis do generate different results when treatment effects are taken into account. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 65-71.	0.9	7
49	Rational decision making in medicine: Implications for overuse and underuse. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 655-665.	0.9	48
50	The Second Mediterranean Seminar on Science Writing, Editing and Publishing (SWEP - 2018), Sarajevo, December 8th, 2018. <i>Acta Informatica Medica</i> , 2018, 26, 284.	0.5	14
51	Evidence to Decision framework provides a structured roadmap for making GRADE guidelines recommendations. <i>Journal of Clinical Epidemiology</i> , 2018, 104, 103-112.	2.4	32
52	Hypomethylating Agents Versus Intensive Chemotherapy in Older Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S201-S202.	0.2	0
53	Bisphosphonates for Patients Diagnosed With Multiple Myeloma. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1483.	3.8	10
54	Impact of spinal needle type on postdural puncture headache among women undergoing Cesarean section surgery under spinal anesthesia: A meta-analysis. <i>Journal of Evidence-Based Medicine</i> , 2018, 11, 136-144.	2.4	14

#	ARTICLE	IF	CITATIONS
55	Elective induction of labor at 39 weeks among nulliparous women: The impact on maternal and neonatal risk. PLoS ONE, 2018, 13, e0193169.	1.1	19
56	Heuristic value-based framework for lung cancer decision-making. Oncotarget, 2018, 9, 29877-29891.	0.8	5
57	Amino Bisphosphonates Are Associated with Decreased Mortality Compared to Non-Amino Bisphosphonates in the Treatment of Multiple Myeloma. Blood, 2018, 132, 5638-5638.	0.6	0
58	How Do ASH Guidelines Panels Make Decisions? Association between Decision Making Factors and the Strength of Recommendations. Blood, 2018, 132, 4707-4707.	0.6	0
59	The Influence of Activity Roles and Use of a Structured Framework on Developing Hematology Clinical Practice Guidelines. Blood, 2018, 132, 2237-2237.	0.6	0
60	Towards theory integration: Threshold model as a link between signal detection theory, fast and frugal trees and evidence accumulation theory. Journal of Evaluation in Clinical Practice, 2017, 23, 49-65.	0.9	19
61	Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease. Journal of Evaluation in Clinical Practice, 2017, 23, 241-250.	0.9	6
62	Monte Carlo decision curve analysis using aggregate data. European Journal of Clinical Investigation, 2017, 47, 176-183.	1.7	5
63	Progress in evidence-based medicine: a quarter century on. Lancet, The, 2017, 390, 415-423.	6.3	626
64	Stakeholders apply the GRADE evidence-to-decision framework to facilitate coverage decisions. Journal of Clinical Epidemiology, 2017, 86, 129-139.	2.4	13
65	Acceptable regret model in the end-of-life setting: Patients require high level of certainty before forgoing management recommendations. European Journal of Cancer, 2017, 75, 159-166.	1.3	11
66	Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review. BMJ Open, 2017, 7, e014661.	0.8	26
67	What does evidence mean? Most languages translate "evidence" into "proof". Journal of Evaluation in Clinical Practice, 2017, 23, 971-973.	0.9	3
68	The predicament of patients with suspected Ebola. The Lancet Global Health, 2017, 5, e657.	2.9	1
69	Many faces of rationality: Implications of the great rationality debate for clinical decision-making. Journal of Evaluation in Clinical Practice, 2017, 23, 915-922.	0.9	55
70	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. Liver Cancer, 2017, 6, 337-348.	4.2	18
71	On evidence-based medicine " Authors' reply. Lancet, The, 2017, 390, 2245-2246.	6.3	1
72	Bisphosphonates in multiple myeloma: an updated network meta-analysis. The Cochrane Library, 2017, CD003188.	1.5	72

#	ARTICLE	IF	CITATIONS
73	The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. The Cochrane Library, 2016, 2016, CD009624.	1.5	38
74	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 389-400.	2.3	62
75	Thrombotic thrombocytopenic purpura: gaining knowledge. Lancet Haematology, the, 2016, 3, e210-e211.	2.2	3
76	Cancer randomized trials showed that dissemination bias is still a problem to be solved. Journal of Clinical Epidemiology, 2016, 77, 84-90.	2.4	4
77	Eliciting regret improves decision making at the end of life. European Journal of Cancer, 2016, 68, 27-37.	1.3	15
78	Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents. JAMA Oncology, 2016, 2, 1499.	3.4	6
79	Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. Journal of Clinical Epidemiology, 2016, 80, 3-7.	2.4	145
80	When are clinical trials beneficial for study patients and future patients? A factorial vignette-based survey of institutional review board members. BMJ Open, 2016, 6, e011150.	0.8	2
81	Activating clinical trials: a process improvement approach. Trials, 2016, 17, 106.	0.7	8
82	Reply. Hepatology, 2016, 63, 1051-1051.	3.6	0
83	World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 2016, 72, 98-106.	2.4	58
84	A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 2016, 70, 111-122.	2.4	47
85	GRADE guidelines system is reproducible when instructions are clearly operationalized even among the guidelines panel members with limited experience with GRADE. Journal of Clinical Epidemiology, 2016, 75, 115-118.	2.4	28
86	Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis. Journal of Clinical Epidemiology, 2016, 70, 123-128.	2.4	16
87	When Should Patients Older Than 70 with Acute Myeloid Leukemia be Treated?. Blood, 2016, 128, 4007-4007.	0.6	1
88	Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients. Blood, 2016, 128, 3998-3998.	0.6	0
89	Improving Hospice Referral: Application of Regret-Based Decision Modeling at End-of-Life Care. Blood, 2016, 128, 535-535.	0.6	0
90	Rationality, practice variation and person-centred health policy: a threshold hypothesis. Journal of Evaluation in Clinical Practice, 2015, 21, 1121-1124.	0.9	22

#	ARTICLE	IF	CITATIONS
91	Rough set theory based prognostic classification models for hospice referral. BMC Medical Informatics and Decision Making, 2015, 15, 98.	1.5	8
92	Effect of Age on Clinical Outcomes in Phase 1 Trial Participants. Cancer Control, 2015, 22, 235-241.	0.7	14
93	Evidence-based medicine meets person-centred care: a collaborative perspective on the relationship. Journal of Evaluation in Clinical Practice, 2015, 21, 1047-1051.	0.9	11
94	Thinking Styles and Regret in Physicians. PLoS ONE, 2015, 10, e0134038.	1.1	29
95	When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology, 2015, 61, 905-914.	3.6	69
96	High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review. Bone Marrow Transplantation, 2015, 50, 1069-1074.	1.3	7
97	Quality of evidence is a key determinant for making a strong GRADE guidelines recommendation. Journal of Clinical Epidemiology, 2015, 68, 727-732.	2.4	39
98	Guideline panels should not GRADE good practice statements. Journal of Clinical Epidemiology, 2015, 68, 597-600.	2.4	150
99	Platelet Transfusion: A Clinical Practice Guideline From the AABB. Annals of Internal Medicine, 2015, 162, 205-213.	2.0	717
100	Modern health care as a game theory problem: reply. European Journal of Clinical Investigation, 2015, 45, 443-443.	1.7	3
101	When is rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation. European Journal of Clinical Investigation, 2015, 45, 485-493.	1.7	50
102	Value-Based Cancer Care and the Excessive Cost of Drugs. JAMA Oncology, 2015, 1, 1301.	3.4	8
103	Modern health care as a game theory problem. European Journal of Clinical Investigation, 2015, 45, 1-12.	1.7	29
104	Platelet transfusion: a systematic review of the clinical evidence. Transfusion, 2015, 55, 1116-1127.	0.8	131
105	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genetics in Medicine, 2015, 17, 63-67.	1.1	16
106	Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of over 600 Patients. Blood, 2015, 126, 2505-2505.	0.6	2
107	Dual Processing Model for Medical Decision-Making: An Extension to Diagnostic Testing. PLoS ONE, 2015, 10, e0134800.	1.1	16
108	Those Responsible for Approving Research Studies Have Poor Knowledge of Research Study Design: a Knowledge Assessment of Institutional Review Board Members. Acta Informatica Medica, 2015, 23, 196.	0.5	15

#	ARTICLE	IF	CITATIONS
109	Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435.	2.3	55
110	Evolution of Treatment Regimens in Multiple Myeloma: A Social Network Analysis. PLoS ONE, 2014, 9, e104555.	1.1	5
111	Indirect Treatment Comparison. The Stata Journal, 2014, 14, 76-86.	0.9	26
112	Human Judgment and Health Care Policy. Population Health Management, 2014, 17, 139-140.	0.8	10
113	Patients' values and preferences of the expected efficacy of hip arthroscopy for osteoarthritis: a protocol for a multinational structured interview-based study combined with a randomised survey on the optimal amount of information to elicit preferences. BMJ Open, 2014, 4, e005536.	0.8	4
114	From hospice to hospital: short-term follow-up study of hospice patient outcomes in a US acute care hospital surveillance system. BMJ Open, 2014, 4, e005196-e005196.	0.8	6
115	Benchmarks for detecting "breakthroughs" in clinical trials: empirical assessment of the probability of large treatment effects using kernel density estimation. BMJ Open, 2014, 4, e005249.	0.8	3
116	Identifying homogenous subgroups for individual patient meta-analysis based on Rough Set Theory. , 2014, 2014, 3434-7.		1
117	Improving the Drug Development Process. JAMA - Journal of the American Medical Association, 2014, 311, 355.	3.8	23
118	Evidence-Based Practice Is Not Synonymous With Delivery of Uniform Health Care. JAMA - Journal of the American Medical Association, 2014, 312, 1293.	3.8	43
119	A Framework to Bridge the Gaps Between Evidence-Based Medicine, Health Outcomes, and Improvement and Implementation Science. Journal of Oncology Practice, 2014, 10, 200-202.	2.5	26
120	Study Design and the Drug Development Process"Reply. JAMA - Journal of the American Medical Association, 2014, 311, 2023.	3.8	0
121	Evaluation of Physicians' Cognitive Styles. Medical Decision Making, 2014, 34, 627-637.	1.2	32
122	Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?. Genetics in Medicine, 2014, 16, 338-346.	1.1	24
123	How to increase value and reduce waste when research priorities are set. Lancet, The, 2014, 383, 156-165.	6.3	1,102
124	Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. The Cochrane Library, 2014, 2014, CD010280.	1.5	33
125	Concordance between decision analysis and matching systematic review of randomized controlled trials in assessment of treatment comparisons: a systematic review. BMC Medical Informatics and Decision Making, 2014, 14, 57.	1.5	5
126	Value of Repeat Head Computed Tomography after Traumatic Brain Injury: Systematic Review and Meta-Analysis. Journal of Neurotrauma, 2014, 31, 78-98.	1.7	42

#	ARTICLE	IF	CITATIONS
127	The EGAPP initiative: lessons learned. <i>Genetics in Medicine</i> , 2014, 16, 217-224.	1.1	45
128	How do physicians decide to treat: an empirical evaluation of the threshold model. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 47.	1.5	42
129	Uncertainty about effects is a key factor influencing institutional review boards' approval of clinical studies. <i>Annals of Epidemiology</i> , 2014, 24, 734-740.	0.9	4
130	Treatment-related harms: What was planned and what was reported? National Cancer Institute's Co-operative group phase III randomized controlled trials: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 354-356.	2.4	4
131	World Health Organization recommendations are often strong based on low confidence in effect estimates. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 629-634.	2.4	62
132	Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1677-1686.	2.0	95
133	Defining Optimum Treatment of Patients With Pancreatic Adenocarcinoma Using Regret-Based Decision Curve Analysis. <i>Annals of Surgery</i> , 2014, 259, 1208-1214.	2.1	16
134	Effect of Initial Conditions on Reproducibility of Scientific Research. <i>Acta Informatica Medica</i> , 2014, 22, 156.	0.5	6
135	Meta-Analysis Evaluating Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation As Front-Line Consolidation in Chronic Lymphocytic Leukemia: Results Do Not Justify This Treatment Approach. <i>Blood</i> , 2014, 124, 1306-1306.	0.6	0
136	Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2013, 2, 10.	2.5	112
137	Critical reflections on value in medicine. <i>Journal of Medicine and the Person</i> , 2013, 11, 69-72.	0.1	3
138	Trial unpredictability yields predictable therapy gains. <i>Nature</i> , 2013, 500, 395-396.	13.7	54
139	GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 726-735.	2.4	950
140	GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomes. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 158-172.	2.4	618
141	Sequence of novel agents in multiple myeloma: An instrumental variable analysis. <i>Leukemia Research</i> , 2013, 37, 1077-1082.	0.4	1
142	Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 654-659.	2.4	34
143	Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: A case study of meta-analyses of multiple myeloma trials. <i>Contemporary Clinical Trials</i> , 2013, 34, 257-261.	0.8	9
144	Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Hematology and Oncology</i> , 2013, 6, 2.	6.9	42

#	ARTICLE	IF	CITATIONS
145	Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy. <i>New England Journal of Medicine</i> , 2013, 368, 1131-1139.	13.9	140
146	Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. <i>Immunotherapy</i> , 2013, 5, 457-466.	1.0	41
147	Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: A multiple-treatment meta-analysis. <i>Cancer Treatment Reviews</i> , 2013, 39, 340-349.	3.4	14
148	Optimal type I and type II error pairs when the available sample size is fixed. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 903-910.e2.	2.4	29
149	Recommendations from the EGAPP Working Group: does genomic profiling to assess type 2 diabetes risk improve health outcomes?. <i>Genetics in Medicine</i> , 2013, 15, 612-617.	1.1	18
150	Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?. <i>Genetics in Medicine</i> , 2013, 15, 517-527.	1.1	64
151	Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. <i>Genetics in Medicine</i> , 2013, 15, 14-24.	1.1	46
152	Colony-Stimulating Factors for Febrile Neutropenia. <i>New England Journal of Medicine</i> , 2013, 369, 284-286.	13.9	2
153	Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?. <i>Leukemia Research and Treatment</i> , 2013, 2013, 1-4.	2.0	8
154	Comparator bias: why comparisons must address genuine uncertainties. <i>Journal of the Royal Society of Medicine</i> , 2013, 106, 30-33.	1.1	29
155	Adherence to antiretroviral therapy in India: A systematic review and meta-analysis. <i>Indian Journal of Community Medicine</i> , 2013, 38, 74.	0.2	35
156	Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2013, 163, 315-325.	1.2	35
157	Multiple Myeloma, Version 1.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 11-17.	2.3	63
158	External validation of A Web-Based Prognostic Tool for Predicting Survival for Patients in Hospice Care. <i>Journal of Palliative Care</i> , 2013, 29, 140-146.	0.4	3
159	Treatment Success in Cancer: Industry Compared to Publicly Sponsored Randomized Controlled Trials. <i>PLoS ONE</i> , 2013, 8, e58711.	1.1	32
160	Trial Sequential Boundaries for Cumulative Meta-Analyses. <i>The Stata Journal</i> , 2013, 13, 77-91.	0.9	48
161	Conservative Management Vs. Allogeneic Hematopoietic Cell Transplantation For Polycythemia Vera: A Systematic Review and Decision-Analysis. <i>Blood</i> , 2013, 122, 5372-5372.	0.6	1
162	At What Level of Collective Equipoise Does a Randomized Clinical Trial Become Ethical for the Members of Institutional Review Board/Ethical Committees?. <i>Acta Informatica Medica</i> , 2013, 21, 156.	0.5	15

#	ARTICLE	IF	CITATIONS
163	Evaluation of spot urine protein to creatinine ratio and 24-hour urine protein quantification for proteinuria in patients with plasma cell dyscrasia.. Journal of Clinical Oncology, 2013, 31, e19516-e19516.	0.8	0
164	Efficacy Of Novel Agents As Maintenance Therapy For Multiple Myeloma: A Direct and Network Meta-Analysis. Blood, 2013, 122, 1945-1945.	0.6	0
165	A Strong Correlation Between Spot Urine Protein To Creatinine Ratio and 24-Hour Urine Protein Quantification For Proteinuria Assessment In Patients With Plasma Cell Dyscrasia. Blood, 2013, 122, 3155-3155.	0.6	0
166	What does randomisation achieve?. Evidence-Based Medicine, 2012, 17, 1-2.	0.6	11
167	Towards a classification model to identify hospice candidates in terminally ill patients. , 2012, 2012, 1278-81.		1
168	Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups. Clinical Cancer Research, 2012, 18, 256-262.	3.2	61
169	New treatments compared to established treatments in randomized trials. The Cochrane Library, 2012, 10, MR000024.	1.5	34
170	Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 628-653.	2.3	153
171	Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1211-1219.	2.3	38
172	Bisphosphonates in multiple myeloma: a network meta-analysis. The Cochrane Library, 2012, , CD003188.	1.5	74
173	Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*. Annals of Internal Medicine, 2012, 157, 49.	2.0	920
174	67 ADVANCING COMPARATIVE EFFECTIVENESS RESEARCH THROUGH NETWORK META-ANALYSIS: INTRAVESICAL THERAPY IN BLADDER CANCER. Journal of Urology, 2012, 187, .	0.2	0
175	Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. Journal of Clinical Epidemiology, 2012, 65, 602-609.	2.4	77
176	Comparison of Mycophenolate Mofetil (MMF) Versus Methotrexate (MTX) for Prevention of Acute Graft-Versus-Host Disease: Results of a Meta-Analysis. Biology of Blood and Marrow Transplantation, 2012, 18, S358-S359.	2.0	0
177	Dual processing model of medical decision-making. BMC Medical Informatics and Decision Making, 2012, 12, 94.	1.5	86
178	Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia, 2012, 26, 582-588.	3.3	65
179	Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplantation, 2012, 47, 1164-1170.	1.3	37
180	When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt. BMC Medical Research Methodology, 2012, 12, 85.	1.4	12

#	ARTICLE	IF	CITATIONS
181	A Flexible Alternative to the Cox Proportional Hazards Model for Assessing the Prognostic Accuracy of Hospice Patient Survival. PLoS ONE, 2012, 7, e47804.	1.1	16
182	Mycophenolate Mofetil versus Methotrexate for Prevention of Acute Graft-Versus-Host Disease: Results of a Systematic Review Limited to Propective Randomized Controlled Studies. Blood, 2012, 120, 4168-4168.	0.6	6
183	Maintenance Therapies for Multiple Myeloma (MM): A Network Meta-Analysis. Blood, 2012, 120, 236-236.	0.6	0
184	Comparative Efficacy of Tandem Autologous Versus Autologous Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2012, 120, 4519-4519.	0.6	0
185	Maintenance Therapies for Multiple Myeloma (MM): A Direct Meta-Analysis. Blood, 2012, 120, 4271-4271.	0.6	0
186	Social Network Analysis (SNA) of Salvage Therapies in Multiple Myeloma (MM). Blood, 2012, 120, 4239-4239.	0.6	0
187	Trial Sequential Analysis in Meta-Analyses of Maintenance Therapies for Multiple Myeloma.. Blood, 2012, 120, 2975-2975.	0.6	0
188	Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. The Cochrane Library, 2011, , CD008818.	1.5	36
189	Treatment of Patients with Multiple Myeloma: An Overview of Systematic Reviews. Acta Haematologica, 2011, 125, 8-22.	0.7	27
190	GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). Journal of Clinical Epidemiology, 2011, 64, 407-415.	2.4	2,130
191	Optimism bias leads to inconclusive results—an empirical study. Journal of Clinical Epidemiology, 2011, 64, 583-593.	2.4	45
192	GRADE guidelines: 5. Rating the quality of evidence—publication bias. Journal of Clinical Epidemiology, 2011, 64, 1277-1282.	2.4	1,355
193	Extensions to Regret-based Decision Curve Analysis: An application to hospice referral for terminal patients. BMC Medical Informatics and Decision Making, 2011, 11, 77.	1.5	17
194	Uncertainty in Clinical Medicine. , 2011, , 299-356.		42
195	Uncertainty and Equipoise: At Interplay Between Epistemology, Decision Making and Ethics. American Journal of the Medical Sciences, 2011, 342, 282-289.	0.4	22
196	The Australian 'FORM' approach to guideline development: The quest for the perfect system. BMC Medical Research Methodology, 2011, 11, 17.	1.4	6
197	Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance. BMC Medical Research Methodology, 2011, 11, 55.	1.4	6
198	Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: A systematic review. American Journal of Hematology, 2011, 86, 18-24.	2.0	39

#	ARTICLE	IF	CITATIONS
199	Rough Set Theory based prognostication of life expectancy for terminally ill patients. , 2011, 2011, 6438-41.		4
200	Implications of the Principle of Question Propagation for Comparative-Effectiveness and "Data Mining" Research. JAMA - Journal of the American Medical Association, 2011, 305, 298.	3.8	16
201	Efficacy Research and Unanswered Clinical Questions"Reply. JAMA - Journal of the American Medical Association, 2011, 306, 709.	3.8	1
202	Designing patient-centric applications for chronic disease management. , 2011, 2011, 3146-9.		9
203	From Efficacy to Effectiveness in the Face of Uncertainty. JAMA - Journal of the American Medical Association, 2011, 305, 2005-6.	3.8	88
204	Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clinical Trials, 2011, 8, 591-600.	0.7	20
205	Social Network Analysis (SNA) of Research Programs In Multiple Myeloma (MM). Blood, 2011, 118, 3144-3144.	0.6	1
206	Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 5142-5142.	0.6	1
207	A Social Network Analysis of Treatment Discoveries in Cancer. PLoS ONE, 2011, 6, e18060.	1.1	4
208	Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on Quality of Treatment Related Harms Reporting: An Analysis of National Cancer Institute's Co-Operative Group Phase III Randomized Controlled Trials. Blood, 2011, 118, 673-673.	0.6	0
209	Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials. Blood, 2011, 118, 508-508.	0.6	0
210	External Validation of Prognostic Models in Terminally Ill Patients,. Blood, 2011, 118, 4186-4186.	0.6	0
211	Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis. Blood, 2011, 118, 1878-1878.	0.6	1
212	Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,. Blood, 2011, 118, 3979-3979.	0.6	9
213	Bisphosphonates in multiple myeloma. , 2010, , CD003188.		27
214	Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica, 2010, 95, 340-342.	1.7	29
215	Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Research and Treatment, 2010, 121, 771-776.	1.1	2
216	A regret theory approach to decision curve analysis: A novel method for eliciting decision makers' preferences and decision-making. BMC Medical Informatics and Decision Making, 2010, 10, 51.	1.5	70

#	ARTICLE	IF	CITATIONS
217	Evidence-based practice guidelines for plasma transfusion. <i>Transfusion</i> , 2010, 50, 1227-1239.	0.8	269
218	Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects_{title}>Systematic Review and Meta-regression Analysis</sub>. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1180.	3.8	524
219	Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. <i>Clinical Trials</i> , 2010, 7, 312-321.	0.7	87
220	Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 341, c4543-c4543.	2.4	257
221	Timing of first-line cancer treatments – Early versus late – A systematic review of phase III randomized trials. <i>Cancer Treatment Reviews</i> , 2010, 36, 621-628.	3.4	12
222	Antithymocyte Globulin (ATG) for Graft-Versus-Host-Disease (GvHD) Prophylaxis In Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT): a Systematic Review and Meta-Analysis.. <i>Blood</i> , 2010, 116, 1513-1513.	0.6	1
223	Role of Iron Supplementation to Erythropoiesis Stimulating Agents In the Management of Chemotherapy-Induced Anemia In Cancer Patients: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2010, 116, 2055-2055.	0.6	6
224	Comparative Effectiveness of Bisphosphonates In Multiple Myeloma. <i>Blood</i> , 2010, 116, 3028-3028.	0.6	2
225	JAMA Published Fewer Industry-Funded Studies after Introducing a Requirement for Independent Statistical Analysis. <i>PLoS ONE</i> , 2010, 5, e13591.	1.1	6
226	Comparative Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 3995-3995.	0.6	0
227	Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia In First Complete Remission: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2010, 116, 3511-3511.	0.6	0
228	Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations. <i>The Journal of Supportive Oncology</i> , 2010, 8, 84-91.	2.3	2
229	The Paradox of Equipoise: The Principle that Drives and Limits Therapeutic Discoveries in Clinical Research. <i>Cancer Control</i> , 2009, 16, 342-347.	0.7	48
230	Risk Prediction Versus Diagnosis: Preserving Clinical Nuance in a Binary World. <i>Annals of Internal Medicine</i> , 2009, 150, 223.	2.0	0
231	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3036-3043.	0.8	132
232	Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. <i>Annals of Oncology</i> , 2009, 20, 520-525.	0.6	302
233	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 2349.	3.8	758
234	Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. <i>The Cochrane Library</i> , 2009, , CD007303.	1.5	98

#	ARTICLE	IF	CITATIONS
235	Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2009, 101, 100-106.	3.0	97
236	Response: Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2009, 101, 966-967.	3.0	5
237	Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2009, 15, 3850-3855.	3.2	25
238	Impact of quality of evidence on the strength of recommendations: an empirical study. <i>BMC Health Services Research</i> , 2009, 9, 120.	0.9	35
239	Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). <i>Trials</i> , 2009, 10, 49.	0.7	28
240	Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 893-902.	2.0	41
241	Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1005-1013.	2.0	116
242	Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1415-1421.	2.0	70
243	Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2009, 373, 1532-1542.	6.3	546
244	SYSTEMATIC REVIEWS FOR PROSTATE CANCER: OVERWHELMING TASK FOR CLINICIANS. <i>Journal of Urology</i> , 2009, 181, 6-6.	0.2	0
245	Epistemologic Inquiries in Evidence-Based Medicine. <i>Cancer Control</i> , 2009, 16, 158-168.	0.7	164
246	Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 908-942.	2.3	112
247	Bisphosphonates in Multiple Myeloma. A Systematic Review and Meta Analysis.. <i>Blood</i> , 2009, 114, 3858-3858.	0.6	1
248	Misconceptions, Challenges, Uncertainty, and Progress in Guideline Recommendations. <i>Seminars in Hematology</i> , 2008, 45, 167-175.	1.8	17
249	Decision-Making When Data and Inferences Are Not Conclusive: Risk-Benefit and Acceptable Regret Approach. <i>Seminars in Hematology</i> , 2008, 45, 150-159.	1.8	26
250	Multiple myeloma: detecting the effects of new treatments. <i>Lancet, The</i> , 2008, 371, 1642-1644.	6.3	10
251	Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2008, 26, 132-149.	0.8	274
252	Recommendations on the Use of ¹⁸ F-FDG PET in Oncology. <i>Journal of Nuclear Medicine</i> , 2008, 49, 480-508.	2.8	978

#	ARTICLE	IF	CITATIONS
253	When Is Diagnostic Testing Inappropriate or Irrational? Acceptable Regret Approach. <i>Medical Decision Making</i> , 2008, 28, 540-553.	1.2	57
254	Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 914.	3.8	657
255	Randomized Trials in Oncology Stopped Early for Benefit. <i>Journal of Clinical Oncology</i> , 2008, 26, 18-19.	0.8	44
256	Treatment Success in Cancer_{title}New Cancer Treatment Successes Identified in Phase 3 Randomized Controlled Trials Conducted by the National Cancer Instituteâ€“Sponsored Cooperative Oncology Groups, 1955 to 2006</sub>. <i>Archives of Internal Medicine</i> , 2008, 168, 632.	4.3	94
257	Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. <i>Blood</i> , 2008, 111, 25-41.	0.6	130
258	A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma. <i>Blood</i> , 2008, 112, 236-236.	0.6	9
259	Efficacy of Hypo-Methylating Agents in the Treatment of Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Blood</i> , 2008, 112, 3632-3632.	0.6	4
260	Cancer- and Chemotherapy-Induced Anemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 536.	2.3	86
261	Hodgkin Disease/Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 594.	2.3	9
262	Thalidomide Versus Bortezomib-Based Regimens for Relapsed Myeloma: Meta-Analysis and Indirect Meta-Analysis. <i>Blood</i> , 2008, 112, 2362-2362.	0.6	0
263	Expectation Bias-the Main Culprit for Large Number of Inconclusive Randomized Controlled Trials in Hematological Malignancies. <i>Blood</i> , 2008, 112, 671-671.	0.6	1
264	When Should Potentially False Research Findings Be Considered Acceptable?. <i>PLoS Medicine</i> , 2007, 4, e26.	3.9	55
265	Treatment Tolerance and Efficacy in Geriatric Oncology: A Systematic Review of Phase III Randomized Trials Conducted by Five National Cancer Instituteâ€“Sponsored Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2007, 25, 1272-1276.	0.8	101
266	Evaluation of Serious Adverse Drug Reactions. <i>Archives of Internal Medicine</i> , 2007, 167, 1041.	4.3	43
267	The Sound and the Fury: Financial Conflicts of Interest in Oncology. <i>Journal of Clinical Oncology</i> , 2007, 25, 3567-3569.	0.8	12
268	Articulating and Responding to Uncertainties in Clinical Research. <i>Journal of Medicine and Philosophy</i> , 2007, 32, 79-98.	0.4	65
269	Evidence-Based Medicine for Rare Diseases: Implications for Data Interpretation and Clinical Trial Design. <i>Cancer Control</i> , 2007, 14, 160-166.	0.7	48
270	A Systematic Review of Quality of Life Associated with Standard Chemotherapy Regimens for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1091-1097.	0.5	40

#	ARTICLE	IF	CITATIONS
271	High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 183-196.	2.0	216
272	Evidence profiles for breast cancer: Benefit/harms data based on the totality of randomized evidence. <i>Cancer Treatment Reviews</i> , 2007, 33, 87-89.	3.4	3
273	Systematic Review of Piperacillin-Induced Neutropenia. <i>Drug Safety</i> , 2007, 30, 295-306.	1.4	44
274	Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?. <i>British Journal of Haematology</i> , 2007, 139, 234-242.	1.2	8
275	Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study.. <i>Blood</i> , 2007, 110, 125-125.	0.6	17
276	Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).. <i>Blood</i> , 2007, 110, 5131-5131.	0.6	1
277	Tandem Versus Single Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials (RCT).. <i>Blood</i> , 2007, 110, 936-936.	0.6	3
278	Multiple Myeloma Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 118.	2.3	43
279	Estimating Net Benefits and Harms of Screening Mammography in Women Age 40 to 49 Years. <i>Annals of Internal Medicine</i> , 2007, 147, 882.	2.0	1
280	Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.. <i>Blood</i> , 2007, 110, 3340-3340.	0.6	0
281	Treatment Success in Cancer.. <i>Blood</i> , 2007, 110, 631-631.	0.6	0
282	Role of High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review and Meta-Analysis.. <i>Blood</i> , 2007, 110, 2872-2872.	0.6	3
283	Are systematic reviews more cost-effective than randomised trials?. <i>Lancet, The</i> , 2006, 367, 2057-2058.	6.3	21
284	Screening mammography at 40â€“49 years: regret or no regret?. <i>Lancet, The</i> , 2006, 368, 2035-2037.	6.3	134
285	Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients. <i>Journal of the National Cancer Institute</i> , 2006, 98, 708-714.	3.0	510
286	High-quality evidence in oncology from 16 June to 18 August 2005: A summary. <i>Cancer Treatment Reviews</i> , 2006, 32, 59-64.	3.4	0
287	High-quality evidence in oncology from 25 August to 27 October 2005: A summary. <i>Cancer Treatment Reviews</i> , 2006, 32, 149-155.	3.4	0
288	High-quality evidence in oncology from 3 November to 24 November, 2005: A summary. <i>Cancer Treatment Reviews</i> , 2006, 32, 239-241.	3.4	0

#	ARTICLE	IF	CITATIONS
289	High-quality evidence in oncology from 1 December to 22 December 2005: a summary. <i>Cancer Treatment Reviews</i> , 2006, 32, 402-405.	3.4	0
290	Cancer treatment reviews welcomes submission of the Cochrane Reviews. <i>Cancer Treatment Reviews</i> , 2006, 32, 243-244.	3.4	1
291	Evidence profiles for colo-rectal cancer: Benefit/harms data based on the totality of randomized evidence. <i>Cancer Treatment Reviews</i> , 2006, 32, 577-580.	3.4	0
292	What kind of evidence do patients and practitioners need: Evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. <i>Cancer Treatment Reviews</i> , 2006, 32, 572-576.	3.4	13
293	Evidence profiles for lung cancer: Benefit/harms data based on the totality of randomized evidence. <i>Cancer Treatment Reviews</i> , 2006, 32, 652-655.	3.4	0
294	Erythropoietin or Darbepoetin for patients with cancer. , 2006, , CD003407.		106
295	In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy. <i>British Journal of Haematology</i> , 2006, 132, 656-658.	1.2	16
296	Evidence and decision making. Commentary on M.R. Tonelli (2006), Integrating evidence into clinical practice: an alternative approach to evidence-based approaches. <i>Journal of Evaluation in Clinical Practice</i> 12, 248-256. <i>Journal of Evaluation in Clinical Practice</i> , 2006, 12, 257-259.	0.9	18
297	Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4867-4874.	0.8	675
298	Plasmapheresis in the Treatment of Renal Failure Associated with Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3585-3585.	0.6	2
299	Role of High-Dose Chemotherapy with Autologous Haematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin's Disease.. <i>Blood</i> , 2006, 108, 5432-5432.	0.6	0
300	Evaluation of New Treatments in Radiation Oncology. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 970.	3.8	78
301	Estimating the mean and variance from the median, range, and the size of a sample. <i>BMC Medical Research Methodology</i> , 2005, 5, 13.	1.4	6,548
302	Use of re-randomized data in meta-analysis. <i>BMC Medical Research Methodology</i> , 2005, 5, 17.	1.4	15
303	Acting on Imperfect Evidence: How Much Regret Are We Ready to Accept?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6822-6825.	0.8	27
304	Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. <i>BMJ: British Medical Journal</i> , 2005, 331, 1295.	2.4	58
305	Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 4198-4214.	0.8	273
306	High-quality evidence in oncology from 22nd June to 26th August 2004: a summary. <i>Cancer Treatment Reviews</i> , 2005, 31, 63-67.	3.4	0

#	ARTICLE	IF	CITATIONS
307	High-quality evidence in oncology from 1st September to 14th October 2004: a summary. <i>Cancer Treatment Reviews</i> , 2005, 31, 155-157.	3.4	0
308	Oncology treatment recommendations can be supported only by 2% of high-quality published evidence. <i>Cancer Treatment Reviews</i> , 2005, 31, 319-322.	3.4	18
309	The challenge of systematic reviews of diagnostic and staging studies in cancer. <i>Cancer Treatment Reviews</i> , 2005, 31, 628-639.	3.4	10
310	High-quality evidence in oncology from 14 April to 12 May 2005: A summary. <i>Cancer Treatment Reviews</i> , 2005, 31, 587-589.	3.4	0
311	High-quality evidence in oncology from 19 May to 9 June 2005: A summary. <i>Cancer Treatment Reviews</i> , 2005, 31, 653-656.	3.4	0
312	Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 455-466.	0.7	17
313	Quality of Reporting of Harms in the NCI Sponsored Phase III Hematological Malignancies Trials.. <i>Blood</i> , 2005, 106, 292-292.	0.6	0
314	Epoetin and Darbepoetin To Treat Cancer Patients: Updated Meta-Analysis Results.. <i>Blood</i> , 2005, 106, 751-751.	0.6	2
315	Are Statistically Non-Significant Findings Necessarily Negative? A Review of All Phase III Randomized Controlled Trials in Hematology Conducted by NCI Sponsored Cooperative Groups.. <i>Blood</i> , 2005, 106, 293-293.	0.6	1
316	Citation Impact of Breakthrough Interventions for Malignant Blood Disorders.. <i>Blood</i> , 2005, 106, 3115-3115.	0.6	0
317	Relationship of Harvest CD34+ and CD3+ Counts To Chronic Graft-Versus-Host Disease (cGVHD), Relapse and Survival Following Sibling Allogeneic Stem Cell Transplant.. <i>Blood</i> , 2005, 106, 1820-1820.	0.6	0
318	Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. <i>BMJ: British Medical Journal</i> , 2004, 328, 22-24.	2.4	263
319	Lifting the fog of uncertainty from the practice of medicine. <i>BMJ: British Medical Journal</i> , 2004, 329, 1419-1420.	2.4	29
320	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2004, 5, 285-285.	2.0	4
321	High-quality evidence in oncology from 20th April to 11th May 2004: a summary. <i>Cancer Treatment Reviews</i> , 2004, 30, 665-667.	3.4	1
322	High-quality evidence in oncology from 18th May to 15th June 2004: a summary. <i>Cancer Treatment Reviews</i> , 2004, 30, 721-723.	3.4	0
323	Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. <i>Blood</i> , 2004, 103, 3271-3277.	0.6	163
324	Well informed uncertainties about the effects of treatment. <i>BMJ: British Medical Journal</i> , 2004, 328, 1018.2.	2.4	1

#	ARTICLE	IF	CITATIONS
325	Systematic Review and Meta-Analysis of Randomized Controlled Trials of Erythropoietin in Multiple Myeloma.. Blood, 2004, 104, 232-232.	0.6	2
326	Detection of Cytokeratin-19 in Peripheral Blood of Breast Cancer Patients: Results from a Systematic Review/Meta-Analysis.. Blood, 2004, 104, 5314-5314.	0.6	0
327	Clinical Equipoise and the Therapeutic Misconception. Hastings Center Report, 2003, 33, 4.	0.7	3
328	Choosing a control intervention for a randomised clinical trial. BMC Medical Research Methodology, 2003, 3, 7.	1.4	43
329	Letter to the Editor. Journal of Law, Medicine and Ethics, 2003, 31, 5-6.	0.4	4
330	Off-study availability of investigational treatments. Lancet, The, 2003, 361, 1302.	6.3	1
331	Evidence-based Oncology section " aims and scope. Cancer Treatment Reviews, 2003, 29, 51-53.	3.4	0
332	Evidence-based oncology in cancer treatment reviews. Cancer Treatment Reviews, 2003, 29, 45-50.	3.4	3
333	Evidence-based Oncology section " policies and scope. Cancer Treatment Reviews, 2003, 29, 121-122.	3.4	1
334	Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncology, The, 2003, 4, 293-304.	5.1	100
335	The Importance of the Preservation of the Ethical Principle of Equipoise in the Design of Clinical Trials: Relative Impact of the Methodological Quality Domains on the Treatment Effect in Randomized Controlled Trials. Accountability in Research, 2003, 10, 301-315.	1.6	35
336	Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients. Journal of Clinical Oncology, 2003, 21, 4615-4626.	0.8	263
337	Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ: British Medical Journal, 2003, 326, 1167-1170.	2.4	1,733
338	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-398.	2.0	374
339	A Systematic Review and Lessons Learned from Early Lung Cancer Detection Trials Using Low-Dose Computed Tomography of the Chest. Cancer Control, 2003, 10, 306-314.	0.7	49
340	Nonmyeloablative Allogeneic Stem-Cell Transplantation for Hematologic Malignancies: A Systematic Review. Cancer Control, 2003, 10, 17-41.	0.7	24
341	High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica, 2003, 88, 1304-15.	1.7	53
342	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-98.	2.0	86

#	ARTICLE	IF	CITATIONS
343	Clinical equipoise and the therapeutic misconception. Hastings Center Report, 2003, 33, 4; author reply 4-5.	0.7	2
344	Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Journal of Clinical Oncology, 2002, 20, 4083-4107.	0.8	393
345	Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood, 2002, 100, 2303-2320.	0.6	196
346	Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. American Journal of Medicine, 2002, 112, 406-411.	0.6	216
347	Overlooking patient outcomes in a meta-analysis of trials of granulocyte colon-stimulating factor. American Journal of Medicine, 2002, 113, 766-768.	0.6	0
348	Bisphosphonates in multiple myeloma. , 2002, , CD003188.		69
349	Priority-setting decisions for new cancer drugs. Lancet, The, 2002, 359, 1525.	6.3	1
350	Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?. Lancet Oncology, The, 2002, 3, 145-153.	5.1	51
351	Erythropoietin improves quality of life—a response. Lancet Oncology, The, 2002, 3, 527.	5.1	3
352	Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer, 2002, 2, 23.	1.1	38
353	Quality and methods of developing practice guidelines. BMC Health Services Research, 2002, 2, 1.	0.9	63
354	At what degree of belief in a research hypothesis is a trial in humans justified?. Journal of Evaluation in Clinical Practice, 2002, 8, 269-276.	0.9	14
355	A data-mining approach to improving Polycythemia Vera diagnosis. Computers and Industrial Engineering, 2002, 43, 765-773.	3.4	16
356	Association between competing interests and conclusions. Denominator problem needs to be addressed. BMJ, The, 2002, 325, 1420; author reply 1420.	3.0	3
357	Is clinical research still too haphazard?. Lancet, The, 2001, 358, 1648.	6.3	11
358	Placebo-Controlled Trials. Annals of Internal Medicine, 2001, 135, 62.	2.0	11
359	Evaluation and appraisal of randomized controlled trials in myeloma. Annals of Oncology, 2001, 12, 1611-1617.	0.6	11
360	The natural history of refractory idiopathic thrombocytopenic purpura. Blood, 2001, 98, 2282-2283.	0.6	18

#	ARTICLE	IF	CITATIONS
361	Acknowledgment of uncertainty: A fundamental means to ensure scientific and ethical validity in clinical research. <i>Current Oncology Reports</i> , 2001, 3, 389-395.	1.8	56
362	Scientific and Ethical Issues in Equivalence Trials. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 1206.	3.8	67
363	Informing Patients of Uncertainty in Clinical Trials—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 2713.	3.8	3
364	A clinical score identified cancer patients with febrile neutropenia at low risk for complications. <i>ACP Journal Club</i> , 2001, 134, 76.	0.1	0
365	Evidentiary challenges to evidence-based medicine. <i>Journal of Evaluation in Clinical Practice</i> , 2000, 6, 99-109.	0.9	40
366	Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. <i>Annals of Oncology</i> , 2000, 11, 1591-1595.	0.6	38
367	The Bleeding Risk and Natural History of Idiopathic Thrombocytopenic Purpura in Patients With Persistent Low Platelet Counts. <i>Archives of Internal Medicine</i> , 2000, 160, 1630.	4.3	343
368	Industry-sponsored research. <i>Lancet, The</i> , 2000, 356, 2194.	6.3	1
369	Acquired anaemias and polycythaemia. <i>Lancet, The</i> , 2000, 356, 596.	6.3	0
370	The uncertainty principle and industry-sponsored research. <i>Lancet, The</i> , 2000, 356, 635-638.	6.3	442
371	Colony stimulating factors for chemotherapy induced febrile neutropenia. , 2000, , CD003039.		19
372	Talking about Treatment. <i>Annals of Internal Medicine</i> , 2000, 132, 94.	2.0	1
373	A Young Man with Lymphocytosis. <i>Cancer Control</i> , 1999, 6, 1-5.	0.7	0
374	Using the Internet to Calculate Clinical Action Thresholds. <i>Journal of Biomedical Informatics</i> , 1999, 32, 168-185.	0.7	11
375	Acceptable regret in medical decision making. <i>Medical Hypotheses</i> , 1999, 53, 253-259.	0.8	66
376	The quality of medical evidence in hematology-oncology. <i>American Journal of Medicine</i> , 1999, 106, 198-205.	0.6	48
377	High-Dose Chemotherapy in the Adjuvant Treatment of Breast Cancer: Benefit/Risk Analysis. <i>Cancer Control</i> , 1998, 5, 394-405.	0.7	22
378	Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. , 1996, 51, 168-170.		20

#	ARTICLE	IF	CITATIONS
379	Equation and Nomogram for Calculation of Testing and Treatment Thresholds. <i>Medical Decision Making</i> , 1996, 16, 198-199.	1.2	14
380	Comparison of the quality of life between HIV-positive haemophilia patients and HIV-negative haemophilia patients. <i>Haemophilia</i> , 1996, 2, 166-172.	1.0	24
381	Concomitant Treatment with Factor IX Concentrates and Antifibrinolytics in Hemophilia B. <i>Acta Haematologica</i> , 1995, 94, 43-48.	0.7	7
382	Lack of prophylactic anticoagulant therapy is not associated with clinical thrombotic complications in patients with hemophilia who undergo orthopedic surgical procedures. <i>American Journal of Hematology</i> , 1995, 50, 229-230.	2.0	4
383	Diagnostic entropy as a function of therapeutic benefit/risk ratio. <i>Medical Hypotheses</i> , 1995, 45, 503-509.	0.8	3
384	HLA-DR53 protects against thrombotic thrombocytopenic purpura/adult hemolytic uremic syndrome. <i>American Journal of Hematology</i> , 1994, 47, 189-193.	2.0	24
385	An Estimation of Life Expectancy: The Method Is a Message. <i>Medical Decision Making</i> , 1993, 13, 245-246.	1.2	4
386	High-Dose Chlorambucil and Dexamethasone for Relapsed Non-Hodgkin's Lymphomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1993, 16, 319-322.	0.6	6
387	Residual mediastinal mass after treatment of Hodgkin's disease: A decision analysis. <i>Medical Hypotheses</i> , 1992, 38, 166-175.	0.8	7
388	Disseminated Intravascular Coagulation after Factor IX Complex Resolved Using Purified Factor IX Concentrate. <i>Annals of Internal Medicine</i> , 1991, 115, 621.	2.0	7
389	Occurrence of high-grade T-Cell lymphoma in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: Case report and review of the literature. <i>American Journal of Hematology</i> , 1991, 36, 63-64.	2.0	15
390	Comparison of Different Treatment strategies for Diffuse Large-cell Lymphomas. <i>Medical Decision Making</i> , 1991, 11, 1-8.	1.2	8
391	Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding. <i>Journal of Clinical Laboratory Analysis</i> , 1990, 4, 430-436.	0.9	29
392	A new algorithm for diagnosis of anemia. <i>Postgraduate Medicine</i> , 1989, 85, 119-130.	0.9	6
393	Differentiated HL-60 promyelocytic leukaemia cells produce a factor inducing differentiation. <i>Leukemia Research</i> , 1987, 11, 259-264.	0.4	5
394	Mathematical Model of Acute Myeloblastic Leukaemia: an Investigation of the Relevant Kinetic Parameters. <i>Cell Proliferation</i> , 1985, 18, 307-319.	2.4	13
395	Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. <i>The Cochrane Library</i> , 0, , .	1.5	0
396	Chemoprevention agents for prostate cancer. <i>The Cochrane Library</i> , 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
397	The Role of Hematopoietic Growth Factors in Managing Patients with Hematologic Malignancies. , 0 , 402-411.		0